Clinical Thresholds of Double-strand Breaks in Sperm's DNA in ART (DSBs)
A Prospective Trial Assessing the Impact of Double-strand Breaks on ART Outcomes and Predicting Its Clinical Thresholds
The goal of this prospective observational study is to learn about the impact of double-strand sperm DNA fragmentation (dsSDF) on assisted reproductive technology (ART) outcomes and to derive clinically relevant threshold values for dsSDF and global sperm DNA fragmentation (SDF) in couples undergoing intracytoplasmic sperm injection (ICSI). The main questions it aims to answer are:
- Can clinically relevant threshold values of dsSDF and global SDF predict live birth rates following ICSI?
- Does elevated dsSDF reduce live birth rates following ICSI? Participants undergoing ICSI as part of their routine fertility treatment will provide semen samples for global SDF and dsSDF assessment using the R10 Plus and R11 Plus kits, respectively, analysed using the LensHooke® X12 platform before and after sperm preparation. SDF and dsSDF assessments will be performed both prior to and following sperm washing for each participant. Embryos will be assessed from fertilization through embryo development, and following embryo transfer, participants will be prospectively followed for clinical outcomes ranging from biochemical pregnancy to live birth.
연구 개요
상세 설명
This prospective, two-centre observational study is designed to evaluate the impact of double-strand sperm DNA fragmentation (dsSDF) on assisted reproductive technology (ART) outcomes and to derive clinically relevant threshold values for dsSDF and global sperm DNA fragmentation (SDF) in couples undergoing intracytoplasmic sperm injection (ICSI). Although conventional sperm DNA fragmentation assays assess overall DNA damage, they do not differentiate between single- and double-strand DNA breaks. Emerging evidence suggests that dsSDF represents a more severe form of genomic damage with limited oocyte repair potential and may therefore have a greater impact on embryological and reproductive outcomes, particularly live birth.
A total of 484 infertile couples undergoing ICSI treatment at two tertiary IVF centres in India will be prospectively recruited based on predefined eligibility criteria. Semen samples will be collected on the day of ICSI following 2-3 days of sexual abstinence. Global SDF and dsSDF assessments will be performed using the LensHooke® X12 platform with the R10 Plus and R11 Plus kits, respectively. SDF testing will be conducted both before and after sperm preparation to evaluate the impact of sperm washing on DNA fragmentation parameters.
Embryos derived from enrolled participants will be prospectively assessed from fertilization through embryo development. Following embryo transfer, participants will be prospectively followed for clinical outcomes including biochemical pregnancy, clinical pregnancy, ongoing pregnancy, miscarriage, and live birth.
Receiver operating characteristic (ROC) curve analysis will be used to derive clinically relevant threshold values for dsSDF and global SDF. Multivariable regression analyses will additionally be performed to evaluate the predictive value of dsSDF and global SDF for ART outcomes while adjusting for potential confounding factors. The findings of this study are expected to improve the clinical interpretation of sperm DNA damage assessment and support the integration of dsSDF into individualized reproductive care.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Vipin Chandra, M.B.B.S., D.G.O.
- 전화번호: 918567971239
- 이메일: drvipinchandra@indiraivf.in
연구 장소
-
-
Karnataka
-
Bangalore, Karnataka, 인도, 560041
- Indira IVF Hospital
-
연락하다:
- Jishnu PS, MSc
- 전화번호: 919645062072
- 이메일: jishnu.ps@indiraivf.in
-
부수사관:
- Shyam Gupta, M.S. (OBGY)
-
수석 연구원:
- Jishnu PS, MSc
-
-
Maharashtra
-
Pune, Maharashtra, 인도, 411014
- Indira IVF Hospital
-
연락하다:
- Rajesh Bhisade, MSc
- 전화번호: 919028034181
- 이메일: rajesh.bhisade@indiraivf.in
-
부수사관:
- Amol Lunkad, M.S. (OBGY)
-
수석 연구원:
- Rajesh Bhisade, MSc
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Males aged 21-55 years undergoing ICSI treatment for male factor infertility.
- Women with age 21-35 for self-oocyte pickup cycles
- Oocyte donor cycles with recipient age of 21-35 years of age
- Sperm with a minimum total motile sperm count of 2.0 million/mL and a minimum volume of 1.2 mL
- Patients not underwent sperm DNA fragmentation testing
- 2-3 days of abstinence prior to intracytoplasmic sperm injection (ICSI).
Exclusion Criteria:
- Severe male factor infertility (azoospermia or severe oligozoospermia; for this study defined as no sperm present or sample with <2 million/ml sperm count)
- Known systemic diseases (e.g., diabetes mellitus).
- Surgically retrieved sperms using testicular sperm aspiration, testicular sperm extraction and percutaneous epididymal sperm aspiration.
- Untreated endometrial or uterine factors or adnexal pathology
- Embryos underwent preimplantation genetic testing for aneuploidy testing.
- Patients with thin endometrium (<7mm)
- Patients opted or underwent donor sperms as the male gamete source.
- Patients underwent antioxidant treatment in last 6 months prior to ICSI treatment.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
ICSI Couples Undergoing SDF and dsSDF Assessment
Infertile couples undergoing intracytoplasmic sperm injection (ICSI) at participating tertiary IVF centres will be prospectively enrolled based on predefined eligibility criteria.
Semen samples collected on the day of ICSI will undergo assessment of global sperm DNA fragmentation (SDF) and double-strand sperm DNA fragmentation (dsSDF) using the LensHooke® X12 platform with the R10 Plus and R11 Plus kits, respectively.
SDF assessments will be performed before and after sperm preparation.
|
The LensHooke® X12 device is an automated sperm DNA fragmentation assessment platform based on the sperm chromatin dispersion (SCD) principle.
In this study, the device will be used to assess global sperm DNA fragmentation (SDF) and double-strand sperm DNA fragmentation (dsSDF) using the R10 Plus and R11 Plus kits, respectively.
The platform incorporates automated image acquisition and analysis to minimize operator-dependent variability and standardize sperm DNA fragmentation assessment.
Semen samples collected from participants undergoing intracytoplasmic sperm injection (ICSI) will be analysed before and after sperm preparation to evaluate the association between sperm DNA damage parameters and assisted reproductive technology (ART) outcomes.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Live Birth rate
기간: 24 weeks post embryo transfer
|
Live birth will be defined as the delivery of one or more live infants at or beyond 24 weeks of gestation following embryo transfer.
Live birth rate will be calculated as the proportion of embryo transfer cycles resulting in at least one live birth.
|
24 weeks post embryo transfer
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Clinical Threshold Values for dsSDF and Global SDF
기간: From fertilization assessment following intracytoplasmic sperm injection (ICSI) until live birth, approximately 18 months after participant enrolment.
|
Clinically relevant threshold values for double-strand sperm DNA fragmentation (dsSDF) and global sperm DNA fragmentation (SDF) will be derived using receiver operating characteristic (ROC) curve analysis based on their predictive ability for live birth and other assisted reproductive technology (ART) outcomes.
Thresholds will be identified as the values associated with a significant reduction in reproductive outcomes following intracytoplasmic sperm injection (ICSI).
|
From fertilization assessment following intracytoplasmic sperm injection (ICSI) until live birth, approximately 18 months after participant enrolment.
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Vipin Chandra, M.B.B.S., D.G.O., Indira IVF Hospital Limited, India
- 연구 책임자: Sandro Esteves, Ph.D., Androfert Clinic, Brazil
- 연구 의자: Naval Shah, MSc, Indira IVF Hospital Limited, India
- 연구 의자: Shashank Sanagoudar, M.S. (OBGY), Indira IVF Hospital Limited, India
- 연구 의자: Divreena Talwar, MSc, Indira IVF Hospital Limited, India
- 연구 의자: Jayesh Shinde, MSc, Indira IVF Hospital Limited, India
- 연구 의자: Vivek Dave, Ph.D., Indira IVF Hospital Limited, India
- 연구 의자: Cherry Yang, MSc, Bonraybio Co. Ltd.
- 연구 의자: Tse-en Wang, Ph.D., Bonraybio Co. Ltd.
- 연구 의자: Santoshi Kadam, ADVY Chemical Private Limited
간행물 및 유용한 링크
일반 간행물
- Alvarez JG, Garcia-Peiro A, Barros A, Ferraz L, Sousa M, Sakkas D. Double strand DNA breaks in sperm: the bad guy in the crowd. J Assist Reprod Genet. 2023 Apr;40(4):745-751. doi: 10.1007/s10815-023-02748-5. Epub 2023 Feb 24.
- Agarwal A, Barbarosie C, Ambar R, Finelli R. The Impact of Single- and Double-Strand DNA Breaks in Human Spermatozoa on Assisted Reproduction. Int J Mol Sci. 2020 May 29;21(11):3882. doi: 10.3390/ijms21113882.
- Wang TE, Lee CI, Huang CC, Tsao HM, Chang HC, Chang LS, Chang TA, Lee MS, Hsu CT. Innovative technology for evaluation of sperm DNA double-strand breaks diagnoses male factor infertility and prevents reproductive failures. Sci Rep. 2023 Nov 3;13(1):18996. doi: 10.1038/s41598-023-46049-4.
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
- IIHL/EMB/PRS_001_2026
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .